Clinical Trial Update: Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca [Phase 1, Phase 2]

View source ↗

Summary

An ongoing Phase 1/2 study of abemaciclib plus ramucirumab for metastatic esophageal adenocarcinoma and metastatic gastroesophageal junction adenocarcinoma; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Esophageal Cancer
• Gastroesophageal Junction Adenocarcinoma
• Gastroesophageal Junction Cancer

Drugs mentioned

• Cyramza (ramucirumab)
• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: Baylor Research Institute | Conditions: Metastatic Esophageal Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING